Kornimate/medical-research-clean huggingface dataset:
back deformity in adolescents students

Conditions: Back Disorder

Summary: 1. determine the prevalence of scoliosis and kyphosis among male adolescents in preparatory and secondary governmental schools in el kharga city. 2. to identify factors affecting aetiology and morphology of scoliosis and kyphosis among male adolescents in governmental preparatory and secondary schools in el kharga city. 3. to assess the effect of scoliosis and kyphosis among male adolescents in governmental preparatory and secondary schools in el kharga city on related life style aspects.

the anterior and posterior curves of concavity are part of the physiological position of the spinal column, and are represented by cervical lordosis, thoracic kyphosis, lumbar lordosis, and new sacral and coccygeal kyphosis. despite all these curves, the spinal column should work mechanically as a straight and rigid axis to withstand stress, and should be functionally flexible in order to allow movement. this mix of opposite behaviors (rigidness and flexibility) is the result of a complex stabilization system formed by muscles that contract and relax harmonically and absorb any impact exerted on the spinal column structure. biomechanically speaking, the spinal column influences and is influenced by positioning and stress of the pelvic and scapular belts, and upper and lower limbs, respectively. postural deformities and alterations should not be evaluated only in terms of bone structure, but also in terms of the functional assembly represented by the spinal column \[2\]. adolescence is a stage of fast physical development in which the nervous system and musculoskeletal system have yet to fully develop. changes in the physical morphology of the spine are known to cause musculoskeletal system conditions, such as non-specific back pain. moreover, the spinal morphology as scoliosis and kyphosis. with early identification and intervention, scoliosis may be prevented from progressing, so that it does not interfere with mobility, activity or comfort. scoliosis has a large percentage that remains asymptomatic,\[4\] therefore the feasibility of screening is worthwhile

Eligibility criteria:
inclusion criteria: * male students from the 2nd and 3rd preparatory levels and 1st secondary level exclusion criteria: * female students
ventilation-drive coupling to evaluate the efficacy of inhaled bronchodilators in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: chronic obstructive pulmonary disease (copd) is a major cause of chronic morbidity, mortality and disability throughout the world, leading to a heavy social and economic burden.bronchodilators, the most commonly used drugs in copd patients, have been shown to reduce dyspnea, improve exercise tolerance and improve health status. however,conventional lung function parameters such as forced vital capacity (fvc) and forced expiratory volume in one second (fev1) frequently fail to detect significant functional responses to bronchodilators in patients with chronic airflow obstruction. it is necessary for clinical and scientific reasons to develop a new tool to objectively assess the effect of different treatments including bronchodilator on copd. our previous study showed that ventilation-drive coupling may be more sensitive and accurate to evaluate the efficacy of inhaled bronchodilators in patients with copd because it could better reflect the pathological and physiological characteristics of copd. based on the above conclusion, the present study were performed using the experimental methods of placebo and self-controlled. we aimd to explore the value of ventilation-drive coupling in evaluating the efficacy of bronchodilators on copd and provide a reasonable basis for the clinical application of this index.

patients were randomly assigned to one of two intervention groups: 1. group a: patients inhaled placebo, ipratropium 80μg, salbutamol 400 μg in sequence; 2. group b: patients inhaled placebo, salbutamol 400μg, ipratropium 80 μg in sequence. the data were collected in 30 minutes after patients inhaled placebo,in 30 minutes after ipratropium and in 15 minutes after salbutamol.

Eligibility criteria:
inclusion criteria: patients aged 40-70 years old; patients with pulmonary function test of fev1/fvc \< 70% and fev1%pred \< 50%; patients in a clinically stable state; patients who signed informed consent. exclusion criteria: patients with signs of an airway infection; patients with an acute exacerbation during the previous 4 weeks; patients with giant bulla(≥3cm in diameter); patients with recent upper abdominal surgery; patients with one or more of the following diseases: esophageal cancer, reflux esophagitis, severe obstructive sleep apnea (apnea hypopnea index\>15/hr), neuromuscular disease, or significant heart failure; patients with poor compliance.

Keywords: copd, central drive, bronchodilators
video-based teach-to-goal intervention on inhaler technique on jordanian adults with asthma and copd

Conditions: COPD; Asthma; Inhaled Steroid Dependent Asthma

Summary: this study was an interventional educational study that was intended to find out the effect of a video based inhaler technique education on improving inhaler technique mastery, disease control, medication adherence and patient quality of life in comparison to verbal education among adults with asthma or copd.


Eligibility criteria:
inclusion criteria: * established diagnosis of asthma or copd. * started on one or more inhaler devices for a minimum of one month. * expected to continue using their inhaler devices chronically. exclusion criteria: * patients at high risk of infection (immunocompromised). * patients presenting with a very severe clinical presentation (severe dyspnoea, confusion due to hypoxemia, the need for continuous oxygen therapy).

Keywords: video-based teach to goal education chronic obstructive pulmonary disease asthma randomized controlled trial patient education quality of life medication adherence inhaler technique
f 18 t807 tau pet imaging of alzheimer's disease

Conditions: Alzheimer Disease

Summary: a single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by pet correlates with cognitive status of individuals with and without brain tau fibrils.

this project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18f-av-1451 (also known as f 18 t807), a novel tau imaging compound, in individuals with and without brain tau fibrils. the primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. the investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.

Eligibility criteria:
inclusion criteria: 1. male or female participants, at least 18 years of age. 2. cognitively normal, or with mild dementia, as assessed clinically 3. participant is able and willing to undergo testing (mri or ct, pet, radioactive tracer injection, lp; for those unable to undergo an mri, ct will be used to generate regions-of-interest). 4. pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration. exclusion criteria: 1. has any condition that, in the investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). 2. is deemed likely unable to perform the imaging procedures for any reason. 3. has a high risk for torsades de pointes or is taking medications known to prolong qt interval. 4. has hypersensitivity to f 18 t807 or any of its excipients. 5. contraindications to pet, pet-ct or mr (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. severe claustrophobia. 7. currently pregnant or breast-feeding. 8. for those electing to undergo the optional lumbar puncture: currently on anticoagulant of any form -

Keywords: dementia tauopathies brain diseases central nervous system diseases mild cognitive impairment nervous system diseases neurodegenerative disease
anti-osteoporosis medication monitoring and management service

Conditions: Osteoporosis; Fracture

Summary: background: one-year adherence to oral anti-osteoporosis medication (aoms) was only about 30%. in recent years, efforts have been made to change the delivery of these medications from oral form to injection form every, 3, 6 or 12 months to increase adherence. however, both patients and providers are sometimes confused about the multiple choices. also, patients may receive extra medications if providers did not keep tract of their previous aom uses or patients may changes providers. there were urgent needs to provide aom monitoring and management services to improve cares. objectives: to establish a anti-osteoporosis medication management service at national taiwan university hospital and its beihu branch. methods: participating physicians will select those eligible for services and refer to study coordinators. study coordinators will conduct baseline assessments on osteoporosis/fracture risks, record medical conditions, aoms, provide educations on osteoporosis, fracture, sarcopenia, fall, medications, nutrition, and exercise. they also arrange return clinic visit, telephone reminder and follow up for patients, and communicate with providers on regular bases. the investigators plan to enroll 500 patients with 18-month follow up for each.


Eligibility criteria:
inclusion criteria: * age \>=50 and one of the below * newly prescribed with aoms * recent change of aoms * poor adherence to aoms * participating physicians feel that the service will benefit the patient in overall osteoporosis and medication managements. exclusion criteria: * life expectancy less than 2 years or can't be assessed for communication problems * patient in our fracture liaison service or other medication clinical trials

Keywords: osteoporosis medication monitoring education adherence management
a study of therapy selected by molecular/metabolic profiling in patients with previously treated metastatic pancreatic cancer

Conditions: Previously Treated Metastatic Pancreatic Cancer

Summary: the purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

following first-line therapy with a gemcitabine based regimen, a significant number of patients will maintain an adequate performance status and be able to tolerate a second-line therapy. a recent phase iii trial randomized patients to either 5-flurouracil (5fu), folinic acid or to the addition of weekly oxaliplatin to the same regimen of 5fu/folinic acid. the interim results showed a statistically significant survival advantage for the oxaliplatin containing arm (26 versus 13 weeks, p= 0.014). however the outcome of patients who have progressed on a first-line gemcitabine regimen is still poor with median survival of about 2-6 months. almost all patients with advanced apc, treated with gemcitabine alone or a gemcitabine based combination therapy will exhibit resistance to therapy. in patients treated with gemcitabine alone, the time to progression (ttp) is about 3-4 months. thus most patients will exhibit progression and /or toxicity and will require second line therapy at 4-6 months into first line therapy. the best one year survival reported in a phase ii trial is only 24%. however there is no standard second line therapy for apc, a rapid progression of tumor is seen in this setting, and new strategies based on rational target identification are needed. in this study we propose to select therapy based on the molecular profiling of each patients tumor.

Eligibility criteria:
inclusion criteria: * metastatic adenocarcinoma of the pancreas * male or non-pregnant female * 18 years of age or greater * one prior therapy for the treatment of metastatic disease * must start continuation therapy within 9 months of starting first line treatment * have adequate organ and bone marrow function * must have a karnofsky performance status greater than or equal to 70 * one or more metastatic tumors measurable by ct scan and accessible for biopsy exclusion criteria: * operable or locally advanced pancreatic cancer * metastatic tumor that is not amendable to biopsy * known brain mets unless previously treated and well controlled * active, uncontrolled bacterial, viral or fungal infections * known infection with hiv, hepatitis b or hepatitis c * pregnant or breast-feeding patients

Keywords: pancreatic cancer molecular profiling su2c second line therapy stage 4
schizophrenia treatment with photoneuromodulation

Conditions: Schizophrenia

Summary: abstract: randomized clinical trial that aims to see the efficacy of photoneuromodulation for the treatment of negative symptoms of schizophrenia in patients refractory to transcranial direct current stimulation. in this group of 30 refractory volunteers, magnetic resonance spectroscopy will be performed before and after photoneuromodulation in a cross-over design. objectives: effectiveness of photoneuromodulation in patients with schizophrenia. . analysis of glutamate, gaba and lactate in spectroscopy before and after stimulation (secondary) sample: 30 volunteers with negative symptoms of schizophrenia refractory to treatment. method: clinical trial, cross-over randomized, double-blind, sham-controlled. panss negative symptoms subscale evaluation before and after the 10 photoneuromodulation sessions. participants who are in the active group after the 10 photoneuromodulation sessions will go to the sham group and vice versa. they will perform magnetic resonance spectroscopy before the beginning, after the 10 sessions and again after the inversion of the groups (3 resonances per volunteer). the study will be a cross-over: half of participants will start at sham group and the other half at active group and invert groups after 10th day of stimulation.


Eligibility criteria:
inclusion criteria: * patients between 18 and 55 years * diagnosis of schizophrenia according to dsm-iv criteria and confirmed by the scid (structured clinical interview for dsmiv), which will be applied by a psychiatrist, will be included. * minimum score of 20 points in the sum of negative panss * stable antipsychotic medications * there is a need for at least one trial with at least one antipsychotic in adequate dose and time to enter the study. exclusion criteria: * unstable or uncontrolled clinical diseases, * psychiatric comorbidities,

Keywords: schizophrenia photoneuromodulation neuromodulation
food effect study with bms-955176

Conditions: Infection, Human Immunodeficiency Virus

Summary: the purpose of this study is to assess the impact of a light meal, a standard meal, and a high fat meal on the pk of bms-955176 mc tablet at a dose of 180 mg, relative to fasted conditions.

primary purpose other: this study will assess the impact of a light meal, a standard meal, and a high fat meal on the pharmacokinetics (pk) of bms-955176 micronized crystalline (mc) tablet at a dose of 180 mg relative to fasted conditions.

Eligibility criteria:
inclusion criteria: * healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead ecg measurements, and clinical laboratory test results * body mass index (bmi) of 18.0 to 32.0 kg/m2, inclusive. bmi = weight (kg)/\[height (m)\]2 * men and women, ages 18 to 50 years, inclusive * women must not be of childbearing potential, must not be breastfeeding exclusion criteria: * any significant acute or chronic medical illness * history of cardiac disease or clinically significant cardiac arrhythmias * current or recent (within 3 months of study drug administration) gastrointestinal disease * any major surgery within 4 weeks of study drug administration * any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug
human papillomavirus (hpv) vaccination acceptance by african-american parents: identifying psychosocial barriers

Conditions: HPV

Summary: this will enroll 300 mothers of teenage girls and boys to identify barriers to hpv vaccination among low-income, african-american teens.

the hpv vaccine offers hope that the incidence of cervical cancer can be greatly reduced in the u.s. and globally. however, because the vaccine is recommended for children and early adolescents, vaccine awareness and acceptance among parents is critical to insuring vaccine uptake and public health benefit. although culturally specific concerns may reduce hpv vaccination among african-american youth, research has not addressed this possibility. accordingly, the proposed study will enroll 300 mothers in a study to identify barriers to hpv vaccination among low-income, african-american teens. surveys assessing culturally-specific barriers to hpv vaccination acceptance will be administered to both parents and their vaccine-eligible children. upon completion of the survey, parents with vaccine-eligible daughters will be invited to receive a free hpv vaccination for their child through a local, teen-friendly health clinic. outcome analyses will focus on identification of predictors of completed vaccinations among girls and barriers to vaccine acceptance among mothers of teenage sons. our study will provide critically important behavioral outcome data linking barriers to vaccination to subsequent vaccination decisions in a real-world, health care setting.

Eligibility criteria:
inclusion criteria: * females parent or guardian with an african-american daughter or son between the ages of 11 and 17 * african-american adolescents between the ages of 11-17

Keywords: hpv gardasil african-american adolescent health behavior sexually transmitted infections this will enroll 300 mothers of teenage girls and boys to identify barriers to hpv vaccination among low-income, african-american teens.
a study of quilizumab versus placebo in patients with refractory chronic spontaneous urticaria

Conditions: Urticaria

Summary: this multicenter, randomized, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of additional quilizumab therapy in adult patients with chronic spontaneous urticaria resistant to antihistamine treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of csu refractory to h1 antihistamines with/without ltras, as defined by the following: * the presence of itch and hives for \> 6 consecutive weeks at any time prior to enrollment despite use of h1 antihistamines during this time period * uas7 score greater than 16 and itch component of uas7 greater than 8 during 7 days prior to day 1. patients must have been on daily stable doses of h1 antihistamine for at least 3 consecutive days immediately prior to the screening visit and must document current use at screening * csu diagnosed for more than 6 months * patients must have a minimum diary compliance (6 out of 7 consecutive days) prior to day 1 exclusion criteria: * treatment with an investigational agent within 30 days of screening, and previous treatment with monoclonal antibody therapies used to treat csu 9 months prior to screening * chronic urticarias other than csu, including the following: acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact. * other diseases and conditions with symptoms of urticaria. * routine doses of the following medications within 30 days prior to screening: systemic or topical corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide * iv immunoglobulin g (ivig), or plasmapheresis within 30 days prior to screening * patients with cancer, history of cancer considered uncured or in complete remission for \< 10 years, or currently under work-up for suspected cancer except non-melanoma skin cancer that has been treated or excised and is considered resolved * history of anaphylactic shock without clearly identifiable avoidable antigen * presence of clinically significant cardiovascular, neurological, psychiatric, metabolic or other pathological conditions. * medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study. * evidence of current drug or alcohol abuse * nursing women and women of childbearing potential, unless using effective contraception as defined by protocol

Keywords: memp1972a
long-term outcome evaluation of patients undergoing autologous chondrocyte transplantation delivered on biomaterial

Conditions: Cartilage Injury; Cartilage Disease

Summary: chondro-long study is prospective observational study for a long-term clinical evaluation (follow-up up to 25 years) in patients treated with autologous chondrocyte transplantation delivered on biomaterial for full-thickness chondral defects (outerbridge grade iii - iv) at the level of femoral condyles, trochlea, patella and tibial plateau. the aim of the study is to collect long-term clinical data from the case series of patients surgically treated from 1999 to 2006 with autologous chondrocyte transplantation delivered on biomaterial for full-thickness chondral defects (outerbridge grade iii - iv) or osteochondral defects at the level of femoral condyles, trochlea, patella, and tibial plateau. the objective of the study is to demonstrate the efficacy of this long-term cartilage regeneration technique (follow-up up to 25 years) in improving patient symptomatology and functional capacity

patients will be recruited from all subjects surgically treated with autologous chondrocyte transplantation delivered on biomaterial for chondral/osteochondral lesions at the femoral condyles, trochlea, patella, and tibial plateau from 1999 to 2006 at the rizzoli orthopaedic institute. the study has 3 phases: identification of includable patients, follow-up assessment bytelemedicine platform, and the collection of study-specific clinical data of enrolled patients. clinical score data will be collected from the medical records and questionnaires conducted in the mid-term of patients enrolled in the study. these data will be used, together with data collected by telemedicine/long-term e-mail questionnaire, to evaluate the time course of outcomes after surgical treatment with autologous chondrocyte transplantation delivered on biomaterial

Eligibility criteria:
inclusion criteria: * patients who underwent autologous chondrocyte transplantation surgery delivered on biomaterial (hyalograft c) from 1999 to 2006 at the rizzoli orthopaedic institute who met the following criteria at the time of surgery: * full-thickness chondral defects (outerbridge grade iii - iv) and osteochondral defects at the femoral condyles, trochlea, patella and tibial plateau. * patients aged between 14 and 60 years at the time of surgery. * male and female sex. exclusion criteria: * patients no longer available

Keywords: autologous chondrocyte transplantation osteochondral defects